The phrase "a consistent superiority" is correct and usable in written English.
It can be used to describe a state of being consistently better or more dominant in comparison to others in a particular context.
Example: "The team's performance demonstrated a consistent superiority over their rivals throughout the season."
Alternatives: "an ongoing advantage" or "a steady dominance".
However, studies comparing CRRT and IHD, using variable definitions of hemodynamic tolerance, have not demonstrated a consistent hemodynamic superiority in CRRT-treated patients [ 4- 8] (Table 5).
In contrast, studies with other LMWHs have not shown consistent superiority over unfractionated heparin.
Hieronymus, F., Emilsson, J. F., Nilsson, S. & Eriksson, E. Consistent superiority of selective serotonin reuptake inhibitors over placebo in reducing depressed mood in patients with major depression.
Letrozole is the only aromatase inhibitor to demonstrate consistent superiority over tamoxifen in this setting [ 53, 54].
The first randomized controlled trials demonstrated consistent superiority for letrozole compared with megestrol acetate, aminoglutethimide, and tamoxifen in patients with advanced breast cancer [ 114– 114].
The consistent superiority of NEPA over PALO across all end points during the delayed phase is particularly opportune, in that patients are protected during a period which has remained a challenge in most clinical settings.
The search for an optimal tuberculosis diagnostic test is motivated by the unacceptably low sensitivity of the conventional ZN smear microscopy over which fluorescence microscopy has shown consistent superiority.
The consistent superiority of NEPA over oral palonosetron across the multiple efficacy endpoints in two comparative studies is particularly noteworthy considering that palonosetron is regarded as a clinically distinct 5-HT3 RA.
Previous findings of the factor structure of the Chinese version of the HADS in Cantonese-speaking Chinese CHD patients in Hong Kong indicates clear and consistent superiority of three-factor models in fits to data [ 20].
As no consistent superiority has been seen with the addition of aprepitant over 5-HT3 RAs + DEX in previous trials evaluating nausea [ 53– 57], it was encouraging to see that a nausea benefit was demonstrated with NEPA over oral palonosetron in two pivotal trials.
